Small Interfering RNA

Transthyretin-directed RNA Interaction

Polyneuropathies

Amyloid Neuropathies, Familial

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><h1>11 DESCRIPTION</h1>AMVUTTRA contains vutrisiran, a chemically modified double-stranded small interfering ribonucleic acid (siRNA) that targets mutant and wild-type transthyretin (TTR) messenger RNA (mRNA) and is covalently linked to a ligand containing three N-acetylgalactosamine (GalNAc) residues to enable delivery of the siRNA to hepatocytes. The structural formula of vutrisiran sodium is presented below.<table class="Noautorules" width="100%"><col align="left" valign="top" width="10%"/><col align="left" valign="top" width="43%"/><col align="left" valign="top" width="47%"/><tbody class="Headless"><tr><td align="left"></td><td align="left" colspan="2"><img alt="Chemical Structure" src="amvuttra-08.jpg"/></td></tr><tr><td align="left"></td><td align="left">Af, Cf, Gf, Uf = 2'-F ribonucleosides Am, Cm, Gm, Um = 2'-OMe ribonucleosides Dashed lines denote Watson-Crick base pairing</td><td align="left">vutrisiran</td></tr></tbody></table><div class="Figure"><img alt="Chemical Formula" src="amvuttra-09.jpg"/></div>The molecular formula of vutrisiran sodium is C530H672F9N171Na43O323P43S6 with a molecular weight of 17,290 Da. The molecular formula of the free acid is C530H715F9N171O323P43S6 with a molecular weight of 16,345 Da.AMVUTTRA is supplied as a sterile, preservative-free, clear, colorless-to-yellow solution for subcutaneous injection. Each 0.5 mL of solution contains 25 mg of vutrisiran (equivalent to 26.5 mg vutrisiran sodium), 0.2 mg sodium phosphate monobasic dihydrate, 0.7 mg sodium phosphate dibasic dihydrate, 3.2 mg sodium chloride, water for injection, and sodium hydroxide and/or phosphoric acid to adjust the pH to ~7.</section>

AMVUTTRA

vutrisiran

0.5 ML vutrisiran 50 MG/ML Prefilled Syringe

Amvuttra

0.5 ML vutrisiran 50 MG/ML Prefilled Syringe [Amvuttra]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Submit MSL Request 

Pharmacy List 

Billing & Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Amvuttra Start Form 

Amvuttra Start Form - Online

Enroll in Patient Savings Program 

Patient Assistance Program 

Treatment Center Locator 

Other HCP Resources 

About Amvuttra 

Side Effects

Receiving Amvuttra

Patient Resources 

Instructions For Use: Polyneuropathy due to Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis)